Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, Zsolt Nagy, Judit Demeter, Szabolcs Kosztolányi, Árpád Szomor, Hussain Alizadeh, Beáta Deák, Tamás Schneider, Márk Plander, Tamás Szendrei, László Váróczy, Árpád Illés, Árpád Bátai, Mónika Pető, Gábor Mikala

Research output: Article

1 Citation (Scopus)

Abstract

Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.

Original languageEnglish
Pages (from-to)1615-1620
Number of pages6
JournalPathology and Oncology Research
Volume25
Issue number4
DOIs
Publication statusPublished - okt. 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this